May 31, 2019 /

Domagrozumab as a Potential Treatment for Duchenne (May 2019)

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

Domagrozumab as a Potential Treatment for Duchenne (May 2019)

On May 22, 2019, Pfizer Inc. joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the primary safety and efficacy results from the Phase 2 clinical trial. Additional details are provided on the on secondary efficacy endpoints and imaging results.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo